Forcyte Biotechnologies

Forcyte Biotechnologies identified a critical gap in drug discovery for mechanical diseases—conditions like asthma, pulmonary fibrosis, and scleroderma where abnormal cellular tension drives pathology. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Researchers and pharmaceutical companies experienced this problem acutely: existing screening methods couldn't measure cell contractility directly, forcing them to rely on indirect biomarkers that often failed to predict clinical efficacy. The problem was measurable but invisible—cells were squeezing abnormally, yet no standard tool quantified this mechanical behavior during drug screening. Alternatives existed but proved inadequate: traditional assays measured downstream effects rather than the mechanical root cause, leading to high failure rates in late-stage development. Early validation came when Forcyte's patented bioMEMS technology demonstrated it could screen hundreds of thousands of compounds while directly measuring cellular force generation. Pharma partners recognized this addressed their fundamental bottleneck: they could now identify mechanically-active drugs earlier, reducing costly failures and accelerating development timelines for diseases where mechanical dysfunction was the primary driver.